Clin2
NCT07493122Possibly a fitNot yet recruiting

Study of IMC-S118AI for Type 1 Diabetes

Type 1 DiabetesType 1 Diabetes (T1D)Diabetes Type 1

Part of Hormones & metabolism, Immune system & allergy clinical trials.

This trial tests a new drug called IMC-S118AI in people with type 1 diabetes. The goal is to see if it can help preserve the remaining function of insulin-making cells in the pancreas, which are important for controlling blood sugar.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
154 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You have type 1 diabetes (not type 2 or other forms).
  • Your body mass index (BMI) is between 18 and 25.
  • You have a specific genetic marker called HLA-A*02:01.
  • Your pancreas still produces some insulin (remaining beta-cell function).
  • You have not taken immune-modulating drugs for diabetes before.
  • You do not have a history of heart disease, cancer, or repeated low blood sugar due to not following insulin plans.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07186660Recruiting· Phase 2
Studying a new insulin sensitizer for type 1 diabetes

This trial tests an oral medication that may help your body respond better to insulin. It's for people with type 1 diabetes who use an automated insulin pump and are willing to take a daily pill for 12 weeks.

Charlottesville, Virginia
NCT07187531Recruiting· Phase 2
Testing a new drug to preserve insulin production in type 1 diabetes

This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.

San Francisco, California
NCT06919354Recruiting· Phase 1
Study of GNTI-122 for new type 1 diabetes

This study tests a new treatment called GNTI-122 for adults recently diagnosed with type 1 diabetes who still make some insulin. It aims to see if the treatment can help protect the cells that produce insulin.

Duarte, California
NCT07699380Recruiting· Phase 2
Metabolic study to improve insulin sensitivity in type 1 diabetes

This study tests a new medication to see if it can improve how your body responds to insulin and boost your cells' energy (mitochondrial function). It is for adults with type 1 diabetes who are already on insulin and have good overall health.

Seattle, Washington
NCT07051564Recruiting
Cell injection study for type 1 diabetes

This trial tests a new cell injection (CNK-UT009) for adults with type 1 diabetes. The goal is to see if it can help manage blood sugar and reduce insulin needs.

Zibo, Shandong
NCT07507708Recruiting
Smart insulin system with behavior support for type 1 diabetes

This study tests a smart insulin pump and continuous glucose monitor system that adjusts insulin automatically and uses behavior support to improve blood sugar control. It's for people with type 1 diabetes who have used an approved automated insulin delivery system recently and are willing to use study devices.

Charlottesville, Virginia

Hear when a new Type 1 diabetes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.